Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

260 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans.
Nauck MA, Kemmeries G, Holst JJ, Meier JJ. Nauck MA, et al. Diabetes. 2011 May;60(5):1561-5. doi: 10.2337/db10-0474. Epub 2011 Mar 23. Diabetes. 2011. PMID: 21430088 Free PMC article. Clinical Trial.
Lack of effect of synthetic human gastric inhibitory polypeptide and glucagon-like peptide 1 [7-36 amide] infused at near-physiological concentrations on pentagastrin-stimulated gastric acid secretion in normal human subjects.
Nauck MA, Bartels E, Orskov C, Ebert R, Creutzfeldt W. Nauck MA, et al. Digestion. 1992;52(3-4):214-21. doi: 10.1159/000200956. Digestion. 1992. PMID: 1459356 Clinical Trial.
Effects of single and combined infusions of human biosynthetic proinsulin and insulin on glucose metabolism and on plasma hormone concentrations in euglycaemic clamp experiments.
Nauck MA, Stöckmann F, Thiery J, Ebert R, Creutzfeldt W. Nauck MA, et al. Horm Metab Res Suppl. 1988;18:60-7. Horm Metab Res Suppl. 1988. PMID: 3056814
Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7-36 amide] in the fasting state in healthy subjects.
Qualmann C, Nauck MA, Holst JJ, Orskov C, Creutzfeldt W. Qualmann C, et al. Among authors: nauck ma. Acta Diabetol. 1995 Mar;32(1):13-6. doi: 10.1007/BF00581038. Acta Diabetol. 1995. PMID: 7612912
Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects.
Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. Deacon CF, et al. Among authors: nauck ma. Diabetes. 1995 Sep;44(9):1126-31. doi: 10.2337/diab.44.9.1126. Diabetes. 1995. PMID: 7657039
Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships.
Ritzel R, Orskov C, Holst JJ, Nauck MA. Ritzel R, et al. Among authors: nauck ma. Diabetologia. 1995 Jun;38(6):720-5. doi: 10.1007/BF00401846. Diabetologia. 1995. PMID: 7672496 Clinical Trial.
Physiological augmentation of amino acid-induced insulin secretion by GIP and GLP-I but not by CCK-8.
Fieseler P, Bridenbaugh S, Nustede R, Martell J, Orskov C, Holst JJ, Nauck MA. Fieseler P, et al. Among authors: nauck ma. Am J Physiol. 1995 May;268(5 Pt 1):E949-55. doi: 10.1152/ajpendo.1995.268.5.E949. Am J Physiol. 1995. PMID: 7762650 Clinical Trial.
Preserved incretin effect in type 1 diabetic patients with end-stage nephropathy treated by combined heterotopic pancreas and kidney transplantation.
Nauck MA, Büsing M, Orskov C, Siegel EG, Talartschik J, Baartz A, Baartz T, Hopt UT, Becker HD, Creutzfeldt W. Nauck MA, et al. Acta Diabetol. 1993;30(1):39-45. doi: 10.1007/BF00572873. Acta Diabetol. 1993. PMID: 8329730
Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.
Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Nauck MA, et al. Diabetologia. 1993 Aug;36(8):741-4. doi: 10.1007/BF00401145. Diabetologia. 1993. PMID: 8405741 Clinical Trial.
Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.
Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Nauck MA, et al. J Clin Invest. 1993 Jan;91(1):301-7. doi: 10.1172/JCI116186. J Clin Invest. 1993. PMID: 8423228 Free PMC article. Clinical Trial.
260 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback